Patents by Inventor Leopold Von Proff

Leopold Von Proff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11579151
    Abstract: The current invention reports a method for producing an antibody comprising the steps of a) providing a plurality of hybridoma cells each expressing an antibody, b) determining the time dependent amount of said antibody bound to the respective antigen by surface plasmon resonance at different temperatures and different antibody concentrations, c) calculating with the time dependent amount determined in b) based on equations (II) to (XIII) at least the thermodynamic parameters (i) standard association binding entropy (?S°‡ass), (ii) standard dissociation binding entropy (?S°‡diss), (iii) standard binding entropy (?S°), (iv) free standard binding enthalpy (?G°), (v) standard dissociation free binding enthalpy (?G°‡diss), (vi) standard association free binding enthalpy (?G°‡ass), (vii) ?T?S°, (viii) dissociation rate constant kd, (ix) equilibrium binding constant KD, and (x) association rate constant ka, d) selecting a hybridoma cell producing an antibody with at least two of the following: i) a standard associa
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: February 14, 2023
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Michael Schraeml, Leopold Von Proff
  • Patent number: 11372000
    Abstract: The present disclosure relates to an antibody that specifically binds a mutated NT-proBNP having i) a mutation substituting arginine at position 46 with histidine or ii) a mutation substituting glutamic acid at position 43 with aspartic acid. Moreover, the present disclosure relates to a mutated NT-proBNP or fragment thereof. Further, envisaged by the present disclosure are kits containing the antibody of the present disclosure, or the mutated NT-proBNP of the present disclosure. The present disclosure also concerns a method for diagnosing heart failure.
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: June 28, 2022
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Klaus Hallermayer, Monika Soukupova, Christina Porzig, Ulrike Kurtkaya, Leopold Von Proff, Sonja Fiesel, Marion Herrmann, Stefanie Kern
  • Publication number: 20220107309
    Abstract: The present invention relates to a monoclonal antibody capable of binding to biotin. In one embodiment the monoclonal antibody according to the invention also does not bind to a biotin moiety on a biotinylated molecule, wherein the biotin moiety is attached to the molecule via the carbon atom of the carboxyl function of the valeric acid moiety of biotin. Also disclosed is a method for generation of an antibody as disclosed herein. The monoclonal antibody according to the invention is of specific use in a method for measuring an analyte in a sample, wherein a (strept)avidin/biotin pair is used to bind a biotinylated analyte specific binding agent to a (strept)avidin coated solid phase.
    Type: Application
    Filed: December 15, 2021
    Publication date: April 7, 2022
    Inventors: Michael GERG, Klaus HIRZEL, Caroline HOJER, Erasmus HUBER, Hans-Peter JOSEL, Thomas MEIER, Michael SCHRAEML, Leopold VON PROFF
  • Publication number: 20220106408
    Abstract: The present invention relates to a monoclonal antibody capable of binding to biotin. In one embodiment the monoclonal antibody according to the invention also does not bind to a biotin moiety on a biotinylated molecule, wherein the biotin moiety is attached to the molecule via the carbon atom of the carboxyl function of the valeric acid moiety of biotin. Also disclosed is a method for generation of an antibody as disclosed herein. The monoclonal antibody according to the invention is of specific use in a method for measuring an analyte in a sample, wherein a (strept)avidin/biotin pair is used to bind a biotinylated analyte specific binding agent to a (strept)avidin coated solid phase.
    Type: Application
    Filed: December 15, 2021
    Publication date: April 7, 2022
    Inventors: Michael GERG, Lars HILLRINGHAUS, Klaus HIRZEL, Caroline Dorothea HOJER, Hans-Peter JOSEL, Christoph SEIDEL, Michael SCHRAEML, Leopold VON PROFF
  • Patent number: 10877030
    Abstract: The current invention is directed to the velocity factor. Based on the velocity factor antibodies can be classified, i.e. antibodies can be characterized on their binding properties as e.g. entropic or enthalpic antigen binder. A velocity factor based classification does not require detailed thermodynamic determinations and/or calculations. The velocity factor is the ratio of the antigen-antibody complex association rate constants ka determined at 37° C. and 13° C. As only two experimental determinations are required to calculate the velocity factor this is a fast and high-throughput suited method.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: December 29, 2020
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Michael Schraeml, Leopold Von Proff
  • Publication number: 20190369117
    Abstract: The present disclosure relates to an antibody that specifically binds a mutated NT-proBNP having i) a mutation substituting arginine at position 46 with histidine or ii) a mutation substituting glutamic acid at position 43 with aspartic acid. Moreover, the present disclosure relates to a mutated NT-proBNP or fragment thereof. Further, envisaged by the present disclosure are kits containing the antibody of the present disclosure, or the mutated NT-proBNP of the present disclosure. The present disclosure also concerns a method for diagnosing heart failure.
    Type: Application
    Filed: August 13, 2019
    Publication date: December 5, 2019
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Klaus Hallermayer, Monika Soukupova, Christina Porzig, Ulrike Kurtkaya, Leopold Von Proff, Sonja Fiesel, Marion Herrmann, Stefanie Kern
  • Publication number: 20190324024
    Abstract: The present invention relates to a monoclonal antibody capable of binding to biotin. In one embodiment the monoclonal antibody according to the invention also does not bind to a biotin moiety on a biotinylated molecule, wherein the biotin moiety is attached to the molecule via the carbon atom of the carboxyl function of the valeric acid moiety of biotin. Also disclosed is a method for generation of an antibody as disclosed herein. The monoclonal antibody according to the invention is of specific use in a method for measuring an analyte in a sample, wherein a (strept)avidin/biotin pair is used to bind a biotinylated analyte specific binding agent to a (strept)avidin coated solid phase.
    Type: Application
    Filed: June 24, 2019
    Publication date: October 24, 2019
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Michael Gerg, Klaus Hirzel, Caroline Dorothea Hojer, Erasmus Huber, Hans-Peter Josel, Thomas Meier, Michael Schraeml, Leopold Von Proff
  • Publication number: 20190309091
    Abstract: The present invention relates to a monoclonal antibody capable of binding to biotin. In one embodiment the monoclonal antibody according to the invention also does not bind to a biotin moiety on a biotinylated molecule, wherein the biotin moiety is attached to the molecule via the carbon atom of the carboxyl function of the valeric acid moiety of biotin. Also disclosed is a method for generation of an antibody as disclosed herein. The monoclonal antibody according to the invention is of specific use in a method for measuring an analyte in a sample, wherein a (strept)avidin/biotin pair is used to bind a biotinylated analyte specific binding agent to a (strept)avidin coated solid phase.
    Type: Application
    Filed: June 24, 2019
    Publication date: October 10, 2019
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Michael Gerg, Lars Hillringhaus, Klaus Hirzel, Caroline Dorothea Hojer, Hans-Peter Josel, Christoph Seidel, Michael Schraeml, Leopold Von Proff
  • Publication number: 20190041397
    Abstract: The current invention reports a method for producing an antibody comprising the steps of a) providing a plurality of hybridoma cells each expressing an antibody, b) determining the time dependent amount of said antibody bound to the respective antigen by surface plasmon resonance at different temperatures and different antibody concentrations, c) calculating with the time dependent amount determined in b) based on equations (II) to (XIII) at least the thermodynamic parameters (i) standard association binding entropy (?S°‡ass), (ii) standard dissociation binding entropy (?S°‡diss), (iii) standard binding entropy (?S°), (iv) free standard binding enthalpy (?G°), (v) standard dissociation free binding enthalpy (?G°‡diss), (vi) standard association free binding enthalpy (?G°‡ass), (vii) ?T?S°, (viii) dissociation rate constant kd, (ix) equilibrium binding constant KD, and (x) association rate constant ka, d) selecting a hybridoma cell producing an antibody with at least two of the following: i) a standard associa
    Type: Application
    Filed: July 5, 2018
    Publication date: February 7, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Michael Schraeml, Leopold Von Proff
  • Publication number: 20170212107
    Abstract: The current invention is directed to the velocity factor. Based on the velocity factor antibodies can be classified, i.e. antibodies can be characterized on their binding properties as e.g. entropic or enthalpic antigen binder. A velocity factor based classification does not require detailed thermodynamic determinations and/or calculations. The velocity factor is the ratio of the antigen-antibody complex association rate constants ka determined at 37° C. and 13° C. As only two experimental determinations are required to calculate the velocity factor this is a fast and high-throughput suited method.
    Type: Application
    Filed: October 6, 2016
    Publication date: July 27, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Michael Schraeml, Leopold Von Proff
  • Patent number: 9488661
    Abstract: The current invention is directed to the velocity factor. Based on the velocity factor antibodies can be classified, i.e. antibodies can be characterized on their binding properties as e.g. entropic or enthalpic antigen binder. A velocity factor based classification does not require detailed thermodynamic determinations and/or calculations. The velocity factor is the ratio of the antigen-antibody complex association rate constants ka determined at 37° C. and 13° C. As only two experimental determinations are required to calculate the velocity factor this is a fast and high-throughput suited method.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: November 8, 2016
    Assignee: Hoffmann-La Roche, Inc.
    Inventors: Michael Schraeml, Leopold Von Proff
  • Patent number: 9341552
    Abstract: The present invention concerns a reagent composition for releasing vitamin D compounds bound to vitamin D-binding protein, a method for the detection of a 25-hydroxyvitamin D compound in which the 25-hydroxyvitamin D compound is released from vitamin D-binding protein using this reagent and the mixture obtained in this manner is analyzed, the use of the reagent to release vitamin D compounds as well as a kit for detecting 25-hydroxyvitamin D which contains the reagent for releasing vitamin D compounds in addition to the usual immunological reagents.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: May 17, 2016
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Apostolos Kyriatsoulis, Susanne Feldmann, Eramus Huber, Nicole Horn, Leopold von Proff, Uwe Kobold, Angela Puhlmann
  • Publication number: 20150104876
    Abstract: The present invention concerns a reagent composition for releasing vitamin D compounds bound to vitamin D-binding protein, a method for the detection of a 25-hydroxyvitamin D compound in which the 25-hydroxyvitamin D compound is released from vitamin D-binding protein using this reagent and the mixture obtained in this manner is analyzed, the use of the reagent to release vitamin D compounds as well as a kit for detecting 25-hydroxyvitamin D which contains the reagent for releasing vitamin D compounds in addition to the usual immunological reagents.
    Type: Application
    Filed: December 18, 2014
    Publication date: April 16, 2015
    Inventors: Apostolos Kyriatsoulis, Susanne Feldmann, Eramus Huber, Nicole Horn, Leopold von Proff, Uwe Kobold, Angela Puhlmann
  • Publication number: 20140256915
    Abstract: The current invention is directed to the velocity factor. Based on the velocity factor antibodies can be classified, i.e. antibodies can be characterized on their binding properties as e.g. entropic or enthalpic antigen binder. A velocity factor based classification does not require detailed thermodynamic determinations and/or calculations. The velocity factor is the ratio of the antigen-antibody complex association rate constants ka determined at 37° C. and 13° C. As only two experimental determinations are required to calculate the velocity factor this is a fast and high-throughput suited method.
    Type: Application
    Filed: November 26, 2013
    Publication date: September 11, 2014
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Michael Schraeml, Leopold Von Proff
  • Publication number: 20140199782
    Abstract: The current invention reports a method for producing an antibody comprising the steps of a) providing a plurality of hybridoma cells each expressing an antibody, b) determining the time dependent amount of said antibody bound to the respective antigen by surface plasmon resonance at different temperatures and different antibody concentrations, c) calculating with the time dependent amount determined in b) based on equations (II) to (XIII) at least the thermodynamic parameters (i) standard association binding entropy (?S°‡ass), (ii) standard dissociation binding entropy (?S°‡diss), (iii) standard binding entropy (?S°), (iv) free standard binding enthalpy (?G°), (v) standard dissociation free binding enthalpy (?G°‡diss), (vi) standard association free binding enthalpy (?G°‡ass), (vii) ?T?S°, (viii) dissociation rate constant kd, (ix) equilibrium binding constant KD, and (x) association rate constant ka, d) selecting a hybridoma cell producing an antibody with at least two of the following: i) a standard associa
    Type: Application
    Filed: December 20, 2013
    Publication date: July 17, 2014
    Applicant: Hoffmann-La Roche Inc.
    Inventors: MICHAEL SCHRAEML, LEOPOLD VON PROFF
  • Patent number: 8645083
    Abstract: The current invention reports a method for producing an antibody comprising the steps of a) providing a plurality of hybridoma cells each expressing an antibody, b) determining the time dependent amount of said antibody bound to the respective antigen by surface plasmon resonance at different temperatures and different antibody concentrations, c) calculating with the time dependent amount determined in b) based on equations (II) to (XIII) at least the thermodynamic parameters (i) standard association binding entropy formula (A), (ii) standard dissociation binding entropy formula (B), (iii) standard binding entropy (?S°), (iv) free standard binding enthalpy (?G°), (v) standard dissociation free binding enthalpy formula (C), (vi) standard association free binding enthalpy formula (D), (vii) ?T?S°, (viii) dissociation rate constant kd, (ix) equilibrium binding constant KD, and (x) association rate constant ka, d) selecting a hybridoma cell producing an antibody with at least two of the following: i) a standard a
    Type: Grant
    Filed: August 25, 2009
    Date of Patent: February 4, 2014
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Michael Schraeml, Leopold Von Proff
  • Patent number: 8617849
    Abstract: The current invention is directed to the velocity factor. Based on the velocity factor antibodies can be classified, i.e. antibodies can be characterized on their binding properties as e.g. entropic or enthalpic antigen binder. A velocity factor based classification does not require detailed thermodynamic determinations and/or calculations. The velocity factor is the ratio of the antigen-antibody complex association rate constants ka determined at 37° C. and 13° C. As only two experimental determinations are required to calculate the velocity factor this is a fast and high-throughput suited method.
    Type: Grant
    Filed: August 19, 2010
    Date of Patent: December 31, 2013
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Michael Schraeml, Leopold Von Proff
  • Publication number: 20120156726
    Abstract: The current invention is directed to the velocity factor. Based on the velocity factor antibodies can be classified, i.e. antibodies can be characterized on their binding properties as e.g. entropic or enthalpic antigen binder. A velocity factor based classification does not require detailed thermodynamic determinations and/or calculations. The velocity factor is the ratio of the antigen-antibody complex association rate constants ka determined at 37° C. and 13° C. As only two experimental determinations are required to calculate the velocity factor this is a fast and high-throughput suited method.
    Type: Application
    Filed: August 19, 2010
    Publication date: June 21, 2012
    Inventors: Michael Schraeml, Leopold Von Proff
  • Patent number: 8003400
    Abstract: The present invention relates to a method of measuring a vitamin D metabolite in a sample, the method comprising the steps of (a) treating said sample with a vitamin D metabolite releasing reagent under conditions appropriate to release a vitamin D metabolite from vitamin D-binding protein and not to cause protein precipitation, (b) subjecting the treated sample obtained in step (a) to a chromatographic separation, and (c) measuring a vitamin D metabolite during or after said chromatographic separation. The present invention also relates to methods for determining the vitamin D status of a subject, for use in the diagnosis of disease, and to agents and kits for use in performing the methods of the invention.
    Type: Grant
    Filed: December 3, 2008
    Date of Patent: August 23, 2011
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Uwe Kobold, Thomas Duelffer, Michael Grol, Rupert Herrmann, Herbert Von der Eltz, Leopold Von Proff
  • Publication number: 20110160436
    Abstract: The current invention reports a method for producing an antibody comprising the steps of a) providing a plurality of hybridoma cells each expressing an antibody, b) determining the time dependent amount of said antibody bound to the respective antigen by surface plasmon resonance at different temperatures and different antibody concentrations, c) calculating with the time dependent amount determined in b) based on equations (II) to (XIII) at least the thermodynamic parameters (i) standard association binding entropy formula (A), (ii) standard dissociation binding entropy formula (B), (iii) standard binding entropy (?S°), (iv) free standard binding enthalpy (?G°), (v) standard dissociation free binding enthalpy formula (C), (vi) standard association free binding enthalpy formula (D), (vii) ?T?S°, (viii) dissociation rate constant kd, (ix) equilibrium binding constant KD, and (x) association rate constant ka, d) selecting a hybridoma cell producing an antibody with at least two of the following: i) a standard a
    Type: Application
    Filed: August 25, 2009
    Publication date: June 30, 2011
    Inventors: Michael Schraeml, Leopold Von Proff